| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Galecto plant IND-Antrag für mutCALR-Antikörper bis Mitte 2026 | 1 | Investing.com Deutsch | ||
| 07.01. | Leerink Partners initiates coverage on Galecto stock with Outperform rating | 2 | Investing.com | ||
| 06.01. | Galecto appoints former Blueprint Medicines executives as COO and CMO | 2 | Seeking Alpha | ||
| 06.01. | Galecto, Inc. - 8-K, Current Report | - | SEC Filings | ||
| GALECTO Aktie jetzt für 0€ handeln | |||||
| 02.01. | Galecto, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 16.12.25 | Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 08.12.25 | Galecto: Guggenheim hebt Kursziel nach positiven ASH25-Daten an | 8 | Investing.com Deutsch | ||
| 08.12.25 | Guggenheim raises Galecto stock price target to $36 on positive ASH25 data | 1 | Investing.com | ||
| 01.12.25 | Guggenheim initiates Galecto stock with Buy rating on DMR-001 potential | 1 | Investing.com | ||
| 01.12.25 | Guggenheim stuft Galecto mit "Buy" ein und sieht Potenzial in Antikörper DMR-001 | 3 | Investing.com Deutsch | ||
| 10.11.25 | Galecto Shares Soar 214% On Damora Therapeutics Acquisition And $285M Funding | 18 | RTTNews | ||
| 10.11.25 | GLTO, MOVE: two penny stocks quadrupled today - but should you buy? | 5 | iNVEZZ.com | ||
| 10.11.25 | Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029 | 8 | Benzinga.com | ||
| 10.11.25 | Galecto-Aktie steigt nach Übernahme von Damora Therapeutics um 360 % | 33 | Investing.com Deutsch | ||
| 10.11.25 | Galecto, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.25 | Galecto, Inc.: Galecto Announces Acquisition of Damora Therapeutics | 285 | GlobeNewswire (Europe) | Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative... ► Artikel lesen | |
| 07.11.25 | Galecto GAAP EPS of -$2.36 | 5 | Seeking Alpha | ||
| 06.11.25 | Galecto, Inc.: Galecto Reports Third Quarter 2025 Operating and Financial Results | 191 | GlobeNewswire (Europe) | BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today... ► Artikel lesen | |
| 06.11.25 | Galecto, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.10.25 | What's Going On With Nano-Cap Galecto Stock On Tuesday? | 10 | Benzinga.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | BioNTech- und Nvidia-Aktien verkauft, Medline und Alphabet rein: Erste 13F-Filings sind da! | Der britische Vermögensverwalter Baillie Gifford hat als einer der ersten sein 13F-Filing für das 4. Quartal abgegeben. Unter den großen Namen im Portfolio gibt es ein paar spannende Veränderungen.... ► Artikel lesen | |
| EVOTEC | 6,148 | +0,79 % | BERENBERG stuft Evotec auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Bewertung von Evotec beim Kursziel von 10 Euro mit "Buy" aufgenommen. Die Hamburger seien ein weltweit anerkanntes Auftragsforschungsinstitut... ► Artikel lesen | |
| AMGEN | 325,15 | +0,06 % | Märkte am Morgen: "KI-Realitätscheck", Wolters Kluwer, AMD, Amgen, Walmart, Novo Nordisk | Die Stimmung an den Aktienmärkten ist derzeit sehr, sehr wechselhaft. Das war gestern deutlich zu spüren. Der DAX war bemerkenswert stark in den Handel gestartet, schloss allerdings leicht im Minus.... ► Artikel lesen | |
| MAINZ BIOMED | 0,945 | -4,51 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,411 | -3,52 % | Breaking News: Tycoon für den Vorstand von NurExone! | ||
| ABIVAX | 98,30 | -0,30 % | ABIVAX Société Anonyme (ABVX): A Bull Case Theory | ||
| IBIO | 1,740 | -14,71 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 56,04 | +2,75 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| GALAPAGOS NV | 28,120 | -2,97 % | Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities | Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,100 | +9,93 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 12,650 | -5,17 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen |